Bure Equity AB

Latest Results (22.09.2026):

Bure Equity AB — Q4 2024 (and full year 2024): Bure reports a strong full‑year 2024 performance with net asset value (NAV) rising to SEK 333.0 per share (up 29.1% vs. year‑end 2023) and group earnings after tax of SEK 5,735M (SEK 77.4 per share). The fourth quarter itself was negative for the Group (Q4 earnings after tax of about SEK –1,291M) as fair‑value changes turned sharply negative in the quarter, but the full‑year value growth was driven mainly by listed holdings such as Mycronic and Yubico.

Net asset value (NAV)

NAV at 31 Dec 2024: SEK 333.0 per share (total NAV SEK 24,689M) — a 29.1% increase vs. 31 Dec 2023 (SEK 257.9). NAV fell 5.0% during Q4 2024 (from SEK 350.3 at quarter start to SEK 333.0). Assets in Treasury represented 3.0% of NAV (vs 8.1% at end‑2023).

Full‑year earnings and EPS

Group earnings after tax, full year 2024: SEK 5,735M (vs SEK 4,749M in 2023). Earnings per share for 2024: SEK 77.4 (64.0). Total return on the Bure share in 2024: 34.5% (SIX Return Index +8.6%).

Q4 2024 result

Fourth quarter 2024: Group earnings from investment activities SEK –1,261M (Q4 2023: +2,990M). Fair‑value changes in financial assets in Q4 were negative (SEK –1,269M). Q4 profit after tax: approximately SEK –1,291M (vs +2,974M in Q4 2023).

Key portfolio drivers

Listed portfolio value increased by SEK 5,795M in 2024. Largest value contributors: Mycronic (+SEK 2,533M), Yubico (+SEK 2,061M), Xvivo Perfusion (+SEK 717M) and Vitrolife (+SEK 437M). Listed companies accounted for ~85.6% of NAV at year‑end; unlisted holdings accounted for ~11.4%.

Major transactions in 2024

Notable investments and deals: acquisition of 14.5% of Mentimeter for SEK 531M; Atle (Bure’s subsidiary) acquisitions including 66% of First Fondene AS and shares in Amaron; Bure bought 700,000 Cavotec shares for SEK 12M; Bure Growth signed a SEK 17M convertible in BioLamina. Bure also made a SEK 45M unconditional contribution to Mercuri and subsequently wrote down that holding (SEK –79M), increasing a promissory‑note loan by SEK 13M.

Dividends and capital policy

The Board proposes an ordinary dividend of SEK 2.75 per share for 2024 (previous year 2.50). During 2024 the Group received dividends totalling SEK 208M and the Parent proposes distributing capital consistent with its dividend proposal.

Cash, treasury & balance sheet highlights

Group cash and cash equivalents at 31 Dec 2024: SEK 646M (1,454 at 31 Dec 2023). Treasury assets fell by SEK 812M to SEK 738M. Parent Company reported net receivables (interest‑bearing) totaling around SEK 985M at year‑end.

Post‑period update

After the balance‑sheet date the report notes NAV of SEK 353.6 per share on 19 Feb 2025 (an increase of 6.2% since year‑end 2024), reflecting continued portfolio value changes.